MICA and neoplasm: To various degrees, Ara-C/DS was able to enhance cancer surface expression of T and NK cell ligands MHC I, MICA/B, and ULBP2/5/6 (Figure 7 and Figure 8), potentially leading to enhanced immune cell clearance through increased tumor immunogenicity.